Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).
Rebecca C ArendBradley J MonkRonnie Shapira-FrommerAshley F HaggertyEdwin A AlvarezAmnon AmitAngeles A SecordCarolyn MullerAntonio Casado HerraezThomas J HerzogKrishnansu S TewariJoshua G CohenMarilyn HuangAdelya YachninLaura L HolemanJonathan A LedermannTamar Rachmilewitz MineiMarc E BuyseShifra Fain ShmueliMichal LaviDror HaratsRichard T Pensonnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The addition of ofra-vec to paclitaxel did not improve PFS or OS. The PFS and ORR in the control arm exceeded the results that were anticipated on the basis of the AURELIA chemotherapy control arm. CA-125 response was a substantial prognostic biomarker for PFS and OS in patients with PROC treated with paclitaxel.